Curated News
By: NewsRamp Editorial Staff
May 28, 2026

NeuroOne Debuts OneRF® Trigeminal Ablation System at ASSFN 2026

Discuss on LinkedIn Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • NeuroOne's new OneRF Trigeminal Nerve Ablation System enables faster, more precise procedures, giving surgeons a competitive edge.
  • The OneRF system uses a multi-contact RF probe for precise mapping and ablation in fewer cycles, reducing procedural time.
  • NeuroOne's technology improves patient comfort and outcomes by reducing hospitalizations and enabling minimally invasive treatments.
  • NeuroOne is developing a SEEG-Drug Delivery System that can deliver drugs, record, and stimulate through a single implant.

Impact - Why it Matters

This news matters because it signals the advancement of minimally invasive treatments for chronic facial pain and neurological disorders. The OneRF® Trigeminal Nerve Ablation System offers a more precise and efficient approach to radiofrequency lesioning, potentially reducing procedure times and improving patient comfort. Additionally, NeuroOne's SEEG-Drug Delivery System could revolutionize how drugs are delivered to the brain, enabling targeted therapy alongside recording and stimulation. For patients, these innovations promise less invasive surgeries, faster recovery, and better outcomes. For the medical community, they represent a step forward in integrating diagnostic and therapeutic capabilities, ultimately enhancing the standard of care in functional neurosurgery.

Summary

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is set to showcase its latest innovations at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Biennial Meeting from May 30 to June 2 in Cleveland. The company will highlight the recently FDA-cleared OneRF® Trigeminal Nerve Ablation System, designed for radiofrequency lesioning to treat chronic facial pain and functional neurosurgical procedures. This system features a multi-contact RF probe that enables precise mapping and ablation in fewer cycles without repositioning, potentially reducing procedural time and improving patient comfort. NeuroOne has completed a limited market release of this system, marking a significant step in commercializing its technology.

In addition, NeuroOne will present its SEEG-Drug Delivery System*, an investigational device that integrates drug delivery with recording, stimulation, and ablation capabilities. Designed for multiple trajectories and repeated dosing through a single implant, this system aims to advance research and treatment options for neurological disorders. The company will also present scientific data, including a presentation on integrating drug delivery into SEEG-based platforms and posters on SEEG-guided radiofrequency ablation and a new multi-contact RF probe for trigeminal neuralgia.

NeuroOne's participation at ASSFN underscores its commitment to transforming neurosurgery. With a portfolio of FDA-cleared products including Evo® electrodes and OneRF® systems, the company focuses on improving surgical outcomes and reducing hospitalizations. The event will also feature neurosurgeon presentations on clinical experiences with NeuroOne's ablation systems, providing real-world insights into their performance and benefits.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne Debuts OneRF® Trigeminal Ablation System at ASSFN 2026

blockchain registration record for this content.